Survodutide

Mechanism of action

Survodutide (Boehringer Ingelheim development code BI 456906, originally Zealand Pharma) is a dual GLP-1 receptor and glucagon receptor agonist — engaging both incretin (GLP-1R) and counter-regulatory (glucagon-R) pharmacology in a single molecule. The two-receptor mechanism is architecturally intermediate between semaglutide (GLP-1R monoagonist), tirzepatide (GLP-1R/GIPR dual agonist), and retatrutide (GLP-1R/GIPR/glucagon-R triple agonist). Survodutide's specific innovation is the GLP-1 + glucagon combination without GIPR involvement. The pharmacological rationale for combining GLP-1R and glucagon-R agonism parallels retatrutide's rationale: GLP-1R engagement drives appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying; glucagon-R engagement drives energy expenditure through hepatic and adipose lipolysis, brown adipose tissue thermogenesis, and fatty-acid oxidation. The strict glucose-dependence of GLP-1-driven insulin secretion prevents the glucagon component from producing significant hyperglycaemia — the same mechanistic argument that supports the glucagon component of retatrutide. The absence of GIPR agonism distinguishes survodutide from tirzepatide and retatrutide. GIPR contributes to insulinotropic effects and modulates lipogenesis; the pharmacological importance of GIPR co-agonism versus GLP-1/glucagon-only combination is an open comparative question that head-to-head trials would clarify. Phase II data suggest survodutide produces weight-loss magnitudes broadly comparable to tirzepatide at optimised dose ranges — consistent with the hypothesis that GLP-1 + glucagon can achieve similar clinical effects to GLP-1 + GIP through different pharmacological routes. Survodutide has received particular attention for MASLD (metabolic-associated steatotic liver disease, formerly NAFLD/NASH). The glucagon-R agonism component is mechanistically well-suited to reducing hepatic fat content — glucagon receptors are highly expressed on hepatocytes and glucagon-mediated hepatic lipid mobilisation is a direct anti-steatotic effect. Survodutide's Phase II MASH trial (Sanyal et al., NEJM 2024) demonstrated substantial hepatic fat reduction and MASH resolution, supporting a specific MASLD/MASH clinical positioning for the compound. Downstream of receptor activation, survodutide produces the integrated GLP-1 + glucagon phenotype: appetite suppression + energy expenditure elevation + direct hepatic lipid mobilisation. This pharmacological footprint distinguishes it from GLP-1 monoagonists (appetite suppression only) and from GLP-1/GIPR dual agonists (appetite suppression + modified adipose metabolism without direct hepatic lipid targeting).

Survodutide's Phase II MASH resolution rate (~83% versus ~18% placebo) is one of the strongest pharmacological signals documented for MASH — an indication with substantial unmet need and limited licensed therapy. The dual GLP-1/glucagon mechanism's direct hepatic lipid-mobilisation effect may position survodutide as a MASH-specific therapy in addition to obesity indications, potentially competing with tirzepatide (recently obtaining EMA MASH approval) and future retatrutide MASH data.

— Notable finding

Research history

Survodutide originated at Zealand Pharma (Denmark), a peptide-therapeutics-focused biotech with a portfolio of dual and triple incretin/counter-regulatory agonists. The compound (originally coded BI 456906 by Boehringer Ingelheim after licensing) was licensed to Boehringer Ingelheim for global development in 2019 as part of Boehringer's expansion into obesity and MASLD therapeutics. Phase I and Phase II development across 2020-2023 established the pharmacokinetic profile (weekly SC dosing), the anticipated dual-receptor pharmacology, and clinical efficacy in obesity and MASLD populations. Phase II obesity data reported in 2024 demonstrated substantial weight loss competitive with tirzepatide (~19% at higher doses), and Phase II MASH data (Sanyal et al., NEJM 2024) demonstrated ~83% MASH resolution rates versus ~18% placebo — a clinical signal that has drawn substantial regulatory and commercial attention. The Phase III SYNCHRONIZE programme initiated in 2023-2024 encompasses SYNCHRONIZE-1 (obesity), SYNCHRONIZE-2 (obesity with type-2 diabetes), and additional trials. The Phase III LIVERAGE programme addresses MASH specifically. First regulatory filings are anticipated 2026-2028 dependent on trial readouts. As of 2026, survodutide is not licensed in any jurisdiction. Access is restricted to Phase III clinical-trial participation. The compound positions Boehringer Ingelheim to compete in the next-generation weight-loss and MASLD therapeutics markets alongside Novo Nordisk (semaglutide, CagriSema) and Eli Lilly (tirzepatide, retatrutide).

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Survodutide's safety profile in Phase II parallels the broader dual-agonist class: gastrointestinal predominance (nausea, vomiting, diarrhoea, constipation) that is dose-dependent and titration-responsive. The glucagon-receptor component has not produced significant hyperglycaemia in Phase II — consistent with retatrutide's Phase II experience and supporting the pharmacological argument that GLP-1-driven glucose lowering compensates for glucagon-driven hepatic glucose mobilisation at clinically relevant doses. A distinctive survodutide safety consideration is modest heart rate elevation, somewhat higher than seen with pure GLP-1R agonists — likely reflecting the glucagon-receptor component's chronotropic effects. Phase III monitoring includes cardiovascular safety endpoints. Hepatic effects are the direction of interest rather than concern — survodutide has demonstrated hepatic fat reduction and improved liver-function markers in MASLD/MASH populations. Transaminase elevations have been favourable direction rather than adverse. The FDA-mandated thyroid C-cell carcinoma class warning is expected to apply based on the class-wide rodent mechanism. Longer-term safety data on rare adverse events (acute pancreatitis, biliary disease, retinopathy) will emerge through the Phase III programme. The Phase II 46-week safety data are encouraging in the expected domains. Phase III will provide the larger and longer-duration dataset required for marketing authorisation.

UK regulatory status

Survodutide is **not** authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds **no marketing authorisation** in any jurisdiction as of 2026. The compound is in Phase III clinical development by Boehringer Ingelheim / Zealand Pharma through the SYNCHRONIZE and LIVERAGE programmes; first regulatory filings are anticipated 2026-2028. Access is restricted to Phase III clinical-trial participation at selected UK NHS and private clinical-trial sites. Supply outside the clinical-trial framework is not legally available through MHRA-regulated channels. As a Phase III dual-agonist with substantial commercial expectations, survodutide has some emerging research-chemical-market presence though less prominent than the more established semaglutide or the flagship-Phase-III retatrutide. Grey-market supply of clinical-development peptides carries substantial safety and regulatory risk pending licensing. Survodutide is not on the WADA Prohibited List; the GLP-1R and glucagon-R class are not currently prohibited. Not a controlled drug under the Misuse of Drugs Act 1971. For animal research under ASPA, survodutide work in vertebrates requires standard project and personal licences.

Frequently asked questions